Eli Lilly And Co vs Vanguard Ultra Short Bond ETF — how do they compare? Eli Lilly And Co trades at $1,213.76 (market cap $1.08T), while Vanguard Ultra Short Bond ETF trades at $49.69. The key difference: Eli Lilly And Co pays a 0.57% dividend while Vanguard Ultra Short Bond ETF pays none. Which is the better fit depends on your goals.
| LLY | VUSB | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.24K | $50.03 |
52-Week Low | $639.43 | $49.60 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →